La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Zhejiang Shouxiangu Pharmaceutical Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Zhen-Yu Li

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	2.3yrs
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

Weak Statutory Earnings May Not Tell The Whole Story For Zhejiang Shouxiangu Pharmaceutical (SHSE:603896)

May 02

AMMINISTRATORE DELEGATO

Zhen-Yu Li (33 yo)

2.3yrs

Mandato

CN¥433,300

Compensazione

Mr. Zhen-Yu Li serves as Managing Director of Zhejiang Shouxiangu Pharmaceutical Co., Ltd. since April 22, 2022.

Zhejiang Shouxiangu Pharmaceutical Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Zhejiang Shouxiangu Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

No independent directors

Recent updates

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Weak Statutory Earnings May Not Tell The Whole Story For Zhejiang Shouxiangu Pharmaceutical (SHSE:603896)

First quarter 2024 earnings released: EPS: CN¥0.39 (vs CN¥0.32 in 1Q 2023)

Zhejiang Shouxiangu Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment improves as stock rises 15%

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.25 in 3Q 2022)

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (SHSE:603896) agreed to acquire Hangzhou Yunhe Hengli Commercial Real Estate Co., Ltd from Hangzhou Yunhe Group Construction Management Co., Ltd. for CNY 0.001 million.

Second quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.13 in 2Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.13 in 2Q 2022)

New minor risk - Shareholder dilution

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 30% to CN¥83.20

Full year 2022 earnings: Revenues miss analyst expectations

No independent directors

Third quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.16 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.071 in 2Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.071 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.092 (vs CN¥0.064 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.23 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.07 (vs CN¥0.88 in FY 2019)

New 90-day low: CN¥33.89

Investor sentiment deteriorated over the past week

New 90-day low: CN¥37.87

New 90-day high: CN¥48.05

Market bids up stock over the past week

New 90-day high: CN¥43.80

Third quarter earnings released

New 90-day high - CN¥41.12

Earnings released

New 90-day high - CN¥40.33

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

AMMINISTRATORE DELEGATO

Mandato

Compensazione